Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Engineering antibody against CD44 for inducing leukemia cell differentation and necrosis

A leukemia cell and apoptosis technology, applied in the direction of antibodies, introduction of foreign genetic material using vectors, anti-tumor drugs, etc., can solve the problems affecting the effectiveness of clinical chemotherapy drugs, hematopoietic cell damage, toxic and side effects of the body, etc., and achieve easy mass production. , the effect of low antigenicity and low production cost

Inactive Publication Date: 2004-12-08
INST OF HEMATOLOGY & BLOOD HOSPITAL CHINESE ACAD OF MEDICAL SCI
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

While these drugs kill leukemia cells, they also seriously damage normal hematopoietic cells, so they have serious toxic and side effects on the body.
In addition, leukemia cells are often resistant to chemotherapy drugs, and the recurrence rate after chemotherapy is high, which seriously affects the effectiveness of clinical chemotherapy drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Engineering antibody against CD44 for inducing leukemia cell differentation and necrosis
  • Engineering antibody against CD44 for inducing leukemia cell differentation and necrosis
  • Engineering antibody against CD44 for inducing leukemia cell differentation and necrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1: HI44a can effectively induce differentiation of leukemia cells

[0034] Take 5ml of bone marrow from a newly treated acute myeloid leukemia patient, separate and extract mononuclear cells, and use 2×10 5 / ml inoculated in a 24-well plate and co-cultured with the differentiation inducer HI44a. The culture condition is RPMI 1640 (containing 10% fetal calf serum), 37°C, 5% CO 2 , Saturated humidity for 4-6 days. After that, the cells were collected to detect changes in differentiation indicators.

[0035] (1) Changes in cell morphology. After leukemia cells are co-cultured with HI44a, they can obviously show the transformation of cell morphology to the direction of maturation. The cells show nuclear pyknosis, reduced nucleoplasm ratio, and reduced nucleolus. Among them, the leukemia cells of M3 and M5 subtypes are the most obvious, see figure 1 .

[0036] (2) Determination of NBT reduction ability. HI44a can significantly increase the NBT reduction ability of leuke...

Embodiment 2

[0062] Example 2 HI44a can effectively induce apoptosis of leukemia cells

[0063] The isolated leukemia cells were co-cultured with HI44a under RPMI 1640 (containing 10% fetal bovine serum), 37°C, 5% CO 2 , Saturated humidity for 48-72 hours, harvest the cells, wash with PBS, Annexin-V kit (Annexin-V-FLOUS staining Kit; ROCHE) to detect early cell apoptosis. After testing, 48-72 hours after HI44a acts on the leukemia cells of 10 patients, the early apoptosis rate of leukemia cells was significantly increased, as shown in Table 4.

[0064] Table 4 The effect of HI44a on early apoptosis of leukemia cells of various subtypes

[0065] Annexin-v positive rate (%)

[0066] FAB subtype Number of cases Control group HI44a group P

[0067] 1 8.18 13.13

[0068] AML2, n=2 2 2.45 40.11

[0069] 1 7.39 9.98

[0070] AML3, n=3 2 2.14 26.84

[0071] 3 59.54 75.77

[0072] 1 4.19 6.89

[0073] AML4, n=2 2 37.06 65.67

...

Embodiment 3

[0078] Example 3 HI44a can inhibit the expression of the proto-oncogene c-myc in leukemia cells, and enhance the expression of the specific differentiation inducing factor M-CSF

[0079] RT-PCR detects the expression changes of c-myc, G-CSF and M-CSF. Leukemia cells were co-cultured with HI44a for 24 hours, and then the cells were collected. Trizol (GIBCO) one-step extraction of total cell RNA, Oligod (T) as a primer, reverse transcription of M-MLV reverse transcriptase into cDNA. The housekeeping gene β-actin was used as an internal control. The primers for PCR amplification are: c-myc, 5'-CCC GAC GCG GGG AGG CTA TT-3' and 5'-TCT CCA GCT GGT CGG CCG TG-3'; G-CSF, 5'-TTG GAC ACACTG CAG CTG GAC GTC GCC GAC TT-3' and 5'-ATT GCA GAG CCA GGGCTG GGG AGC AGT CAT AGT-3'; M-CSF, 5'-CAG TCA GAT GGA GACCTC GT-3' and 5'-GGT GTC TCA TAG AAA GTT CG-3'. (The primers were synthesized by Shanghai Sangon Company). The PCR reaction conditions were: c-myc, denaturation at 94°C for 45s, annealing at ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An engineering antibody CD44 for inducing the differentiation and wither of leukemia cells, the gene in the heavy chain and light chain variable region of monoclonal antibody HI44a of CD44, the polypeptide coded by said gene, the carrier containing said gene, and the application of said gene and polypeptide in preparing medicines for diagnosing and treating leukemia and disclosed.

Description

Technical field [0001] The present invention relates to an antibody for treating leukemia, especially an anti-CD44 engineered antibody for inducing differentiation and apoptosis of leukemia cells. Background technique [0002] Acute leukemia is one of the main diseases that threaten human life and health. In the United States, 2.7 out of 100,000 adults suffer from AML every year, and among adults over 65, this number reaches 14.1. It is a type of malignant disease originating from hematopoietic (or lymphoid) stem cells. Due to the damage of stem cells, leukemia cells lose the ability to further differentiate and mature, or the proliferation and differentiation capabilities are not balanced, and are stagnated at different stages of cell development, which is specifically manifested in the immortal proliferation of cells in the body, and their differentiation, maturation and apoptosis are blocked. Therefore, the treatment of leukemia can be started from three aspects: induction of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61P35/00C07K16/00C12N15/62C12N15/63
Inventor 韩忠朝宋国丽
Owner INST OF HEMATOLOGY & BLOOD HOSPITAL CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com